When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia

The measurement of minimal residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL) has become the most important prognostic tool of, and the backbone to, upfront risk stratification. While MRD assessment is the standard of care for assessing response and predicting outcomes for pediat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamble, Adam, Phelan, Rachel, Burke, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532574/
https://www.ncbi.nlm.nih.gov/pubmed/28686179
http://dx.doi.org/10.3390/jcm6070066
_version_ 1783253485250150400
author Lamble, Adam
Phelan, Rachel
Burke, Michael
author_facet Lamble, Adam
Phelan, Rachel
Burke, Michael
author_sort Lamble, Adam
collection PubMed
description The measurement of minimal residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL) has become the most important prognostic tool of, and the backbone to, upfront risk stratification. While MRD assessment is the standard of care for assessing response and predicting outcomes for pediatric patients with ALL receiving chemotherapy, its use in allogeneic hematopoietic stem cell transplant (HSCT) has been less clearly defined. Herein, we discuss the importance of MRD assessment during the peri-HSCT period and its role in prognostication and management.
format Online
Article
Text
id pubmed-5532574
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-55325742017-08-08 When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia Lamble, Adam Phelan, Rachel Burke, Michael J Clin Med Review The measurement of minimal residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL) has become the most important prognostic tool of, and the backbone to, upfront risk stratification. While MRD assessment is the standard of care for assessing response and predicting outcomes for pediatric patients with ALL receiving chemotherapy, its use in allogeneic hematopoietic stem cell transplant (HSCT) has been less clearly defined. Herein, we discuss the importance of MRD assessment during the peri-HSCT period and its role in prognostication and management. MDPI 2017-07-07 /pmc/articles/PMC5532574/ /pubmed/28686179 http://dx.doi.org/10.3390/jcm6070066 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lamble, Adam
Phelan, Rachel
Burke, Michael
When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia
title When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia
title_full When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia
title_fullStr When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia
title_full_unstemmed When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia
title_short When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia
title_sort when less is good, is none better? the prognostic and therapeutic significance of peri-transplant minimal residual disease assessment in pediatric acute lymphoblastic leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532574/
https://www.ncbi.nlm.nih.gov/pubmed/28686179
http://dx.doi.org/10.3390/jcm6070066
work_keys_str_mv AT lambleadam whenlessisgoodisnonebettertheprognosticandtherapeuticsignificanceofperitransplantminimalresidualdiseaseassessmentinpediatricacutelymphoblasticleukemia
AT phelanrachel whenlessisgoodisnonebettertheprognosticandtherapeuticsignificanceofperitransplantminimalresidualdiseaseassessmentinpediatricacutelymphoblasticleukemia
AT burkemichael whenlessisgoodisnonebettertheprognosticandtherapeuticsignificanceofperitransplantminimalresidualdiseaseassessmentinpediatricacutelymphoblasticleukemia

Ejemplares similares